In this episode, we break down the landmark CAPE COD trial and what it means for treating severe community-acquired pneumonia. Discover how early hydrocortisone use can significantly reduce mortality and the need for mechanical ventilation in critically ill patients, and why that is reshaping clinical practice. We also explore contrasting evidence from other studies, fueling an ongoing debate about when steroids truly make a difference. From patient selection to risks like hyperglycemia, we unpack the nuance behind the headlines. Tune in to understand where the evidence stands and how it is changing the way clinicians approach severe pneumonia.